Nanoparticles in the clinic
Open accessAbstract
Nanoparticle/microparticle‐based drug delivery systems for systemic (i.e., intravenous) applications have significant advantages over their nonformulated and free drug counterparts. For example, nanoparticle systems are capable of delivering therapeutics and treating areas of the body that other delivery systems cannot reach. As such, nanoparticle drug delivery and imaging systems are one of the most investigated systems in preclinical and clinical settings. Here, we will highlight the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and discuss their overall potential in influencing clinical care. In particular, we will focus on current clinical trials for nanoparticle formulations that have yet to be clinically approved. Additional emphasis will be on clinically approved nanoparticle systems, both for their currently approved indications and their use in active clinical trials. Finally, we will discuss many of the often overlooked biological, technological, and study design challenges that impact the clinical success of nanoparticle delivery systems.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanosystems have been the subject of intensive research over the past few decades, resulting in FDA-approved chemotherapeutics, anaesthetics, imaging agents, nutritional supplements and others.
“Nanosystems have been the subject of intensive research over the past few decades, resulting in Food and Drug Administration (FDA)-approved chemotherapeutics, anaesthetics, imaging agents, nutritional supplements and others 6 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710 · see citing works
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852 · see citing works
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
Gupta, A. K., & Gupta, M. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.10.012 · Cited by 6,795 · see citing works
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289 · see citing works
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · see citing works
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733 · see citing works
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523 · see citing works
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., Hazle, J. D., Halas, N. J., & West, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232479100 · Cited by 3,961 · see citing works
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651 · see citing works
Fang, J. Q., Nakamura, H., & Maeda, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,573 · see citing works
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,521 · see citing works
Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · see citing works
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V. S., Torchilin, V. P., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,924 · see citing works
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,508 · see citing works
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032 · see citing works
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860 · see citing works
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · see citing works
Inorganic Nanoparticles for MRI Contrast Agents
Na, H. B., Song, I. C., & Hyeon, T. (2009) · Advanced Materials · doi:10.1002/adma.200802366 · Cited by 1,776 · see citing works
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic‐Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,734 · see citing works
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon‐Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,732 · see citing works
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702 · see citing works
Self-citationMultifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,674 · see citing works
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,631 · see citing works
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyák, K. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,596 · see citing works
PEGylated nanoparticles for biological and pharmaceutical applications
Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00226-0 · Cited by 1,587 · see citing works
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575 · see citing works
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W. C., Farokhzad, O. C., Barry, S. T., Gabizón, A., Grodzinski, P. A., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,489 · see citing works
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · see citing works
Wang, Y.-X. J., Hussain, S. M., & Krestin, G. P. (2001) · European Radiology · doi:10.1007/s003300100908 · Cited by 1,381 · see citing works
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,266 · see citing works
Self-citationPersonalized medicine: Time for one-person trials
Schork, N. J. (2015) · Nature · doi:10.1038/520609a · Cited by 1,229 · see citing works
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M. S., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S., Nguyen, D. N., Fuller, J. E., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,228 · see citing works
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. I. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221 · see citing works
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173 · see citing works
Hrkach, J. S., Hoff, D. D. V., Ali, M. M., Andrianova, E. A., Auer, J., Campbell, T., Witt, D. D., Figa, M. A., Figueiredo, M., Horhota, A. T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147 · see citing works
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144 · see citing works
Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022 · see citing works
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 979 · see citing works
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969 · see citing works
Multifunctional magnetic nanoparticles for targeted imaging and therapy
MCCARTHY, J., & WEISSLEDER, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.014 · Cited by 892 · see citing works
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834 · see citing works
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 815 · see citing works
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 794 · see citing works
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 772 · see citing works
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
Phillips, E. H., Medina, O. P., ZANZONICO, P. B., Carvajal, R. D., Pauliah, M., Ye, Y., Humm, J. L., Gönen, M., Kalaigian, H., Schöder, H. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 716 · see citing works
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1× · see citing works
“The lone nonliposomal nanoparticle system currently approved for cancer treatments is Abraxane, which is an albumin-bound paclitaxel nanoparticle.(33) The majority of these formulations are not PEGylated, with the exception of Doxil and Onivyde,(34) which is perhaps surprising given the widely known advantages even sm…”
BackgroundSelf‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629 · see citing works
Inorganic nanoparticles for cancer imaging and therapy
Huang, H., Barua, S., Sharma, G., Dey, S. K., & Rege, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.004 · Cited by 620 · see citing works
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 610 · see citing works
Steps toward mapping the human vasculature by phage display
Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardó‐Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P., Yao, V. J., Vidal, C. I., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-121 · Cited by 606 · see citing works
Schutt, E. G., Klein, D. H., Mattrey, R., & Riess, J. G. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200550 · Cited by 546 · see citing works
Seven challenges for nanomedicine
Sanhai, W. R., Sakamoto, J. H., Canady, R., & Mauro Ferrari, B. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.114 · Cited by 538 · see citing works
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 523 · see citing works
Self-citationYoo, J., Chambers, E., & Mitragotri, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791920496 · Cited by 522 · see citing works
Self-citationSchmidt-Erfurth, U., & Hasan, T. G. (2000) · Survey of Ophthalmology · doi:10.1016/s0039-6257(00)00158-2 · Cited by 519 · see citing works
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509 · see citing works
Self-citationSilverman, J. A., & Deitcher, S. R. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474 · see citing works
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier
Tang, B. C., Dawson, M., Lai, S. K., Wang, Y.-Y., Suk, J. S., Yang, M., Zeitlin, P., Boyle, M. P., Fu, J., & Hanes, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905998106 · Cited by 453 · see citing works
Madias, N. E., & Harrington, J. T. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90825-2 · Cited by 453 · see citing works
Zuckerman, J. E., Gritli, I., Tolcher, A. W., Heidel, J. D., Lim, D. W., Morgan, R. J., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 436 · see citing works
Klibanov, A. L. (2006) · Investigative Radiology · doi:10.1097/01.rli.0000199292.88189.0f · Cited by 424 · see citing works
Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles
Ruoslahti, E. I. (2012) · Advanced Materials · doi:10.1002/adma.201200454 · Cited by 418 · see citing works
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L. I. F., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417 · see citing works
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390 · see citing works
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 386 · see citing works
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 377 · see citing works
Nanoscale Radiotherapy with Hafnium Oxide Nanoparticles
Maggiorella, L., Barouch, G., Devaux, C., Pottier, A., Deutsch, É., Bourhis, J., Borghi, E., & Lévy, L. (2012) · Future Oncology · doi:10.2217/fon.12.96 · Cited by 373 · see citing works
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Bobbin, M. L., & Rossi, J. J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103633 · Cited by 352 · see citing works
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Li, M., Al‐Jamal, K. T., Kostarelos, K., & Reineke, J. (2010) · ACS Nano · doi:10.1021/nn1018818 · Cited by 351 · see citing works
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C. E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310 · see citing works
Lipid-based nano-delivery systems for skin delivery of drugs and bioactives
Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00219 · Cited by 304 · see citing works
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
Herzog, C., Hartmann, K., Künzi, V., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.029 · Cited by 292 · see citing works
Schultheis, B. S., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C. M., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 262 · see citing works
Leonard, R. C., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257 · see citing works
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N. N., Nemunaitis, J. J., Nemunaitis, D., Bedell, C., Edelman, G. M., Barve, M. A., Nunan, R., Pirollo, K. F., Rait, A. S., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 250 · see citing works
Tumor Heterogeneity and Personalized Medicine
Longo, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejme1200656 · Cited by 246 · see citing works
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W. A., Chung, V. M., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 234 · see citing works
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
BOVIER, P. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.8.1141 · Cited by 233 · see citing works
Henry, B., Neill, D. R., Becker, K. A., Gore, S., Bricio-Moreno, L., Ziobro, R., Edwards, M. J., Mühlemann, K., Steinmann, J., Kleuser, B., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3037 · Cited by 229 · see citing works
AmBisome (Liposomal Amphotericin B): A Comparative Review
Boswell, G. W., Buell, D. N., & Bekersky, I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04464.x · Cited by 227 · see citing works
Yaseen, A. D. B., Kawaguchi, T., & Jankowiak, R. (2009) · International Journal of Nanomanufacturing · doi:10.1504/ijnm.2009.028116 · Cited by 218 · see citing works
Structure, chemistry, and pharmacokinetics of intravenous iron agents.
Danielson, B. G. (2004) · PubMed · doi:10.1097/01.asn.0000143814.49713.c5 · Cited by 208 · see citing works
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K., Burnett, J., & Rossi, J. J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 206 · see citing works
Ultrasmall Sub-10 nm Near-Infrared Fluorescent Mesoporous Silica Nanoparticles
Ma, K., Sai, H., & Wiesner, U. B. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3049783 · Cited by 203 · see citing works
Bhattacharyya, J., Bellucci, J. J., Weitzhandler, I., McDaniel, J. R., Spasojević, I., Li, X.-H., Lin, C.-C., Chi, J., & Chilkoti, A. (2015) · Nature Communications · doi:10.1038/ncomms8939 · Cited by 201 · see citing works
Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm
Howard, M. D., Zern, B. J., Anselmo, A. C., Shuvaev, V. V., Mitragotri, S., & Muzykantov, V. R. (2014) · ACS Nano · doi:10.1021/nn500136z · Cited by 197 · see citing works
Self-citationStern, J. M., Solomonov, V. V. K., Sazykina, E., Schwartz, J. A., Gad, S. C., & Goodrich, G. P. (2015) · International Journal of Toxicology · doi:10.1177/1091581815600170 · Cited by 196 · see citing works
Wibroe, P. P., Ahmadvand, D., Oghabian, M. A., Yaghmur, A., & Moghimi, S. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.021 · Cited by 196 · see citing works
Clinical translation of nanomedicines
Svenson, S. (2012) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2012.10.001 · Cited by 176 · see citing works
Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175 · see citing works
CUMMINGS, G. C., DIXON, J., Kay, N. H., WINDSOR, J. P. W., Major, E., Morgan, M. K., Sear, J. W., Spence, A. A., & Stephenson, D. (1984) · Anaesthesia · doi:10.1111/j.1365-2044.1984.tb06425.x · Cited by 165 · see citing works
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101
Svenson, S., Wolfgang, M., Hwang, J., Ryan, J. L., & Eliasof, S. D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.007 · Cited by 153 · see citing works
Engineering Iron Oxide Nanoparticles for Clinical Settings
Cortajarena, A. L., Ortega, D., Ocampo, S. M., Gonzalez-García, A., Couleaud, P., Miranda, R., Belda-Iniesta, C., & Ayuso‐Sacido, Á. (2014) · Nanobiomedicine · doi:10.5772/58841 · Cited by 151 · see citing works
Eliasof, S. D., Lazarus, D. D., Peters, C. G., Case, R. I., Cole, R. O., Hwang, J., Schluep, T., Chao, J., Lin, J. L., Yen, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309566110 · Cited by 144 · see citing works
Mifamurtide for the treatment of nonmetastatic osteosarcoma
Ando, K., Mori, K., Corradini, N., Rédiní, F., & Heymann, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.543129 · Cited by 144 · see citing works
Size-dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields
Moran, C. H., Wainerdi, S. M., Cherukuri, T. K., Kittrell, C., Wiley, B. J., Nicholas, N., Curley, S. A., Kanzius, J. S., & Cherukuri, P. (2009) · Nano Research · doi:10.1007/s12274-009-9048-1 · Cited by 143 · see citing works
Strumberg, D., Schultheis, B. S., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., & Drevs, J. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp50076 · Cited by 137 · see citing works
Self‐Assembled DNA Nanoclews for the Efficient Delivery of CRISPR–Cas9 for Genome Editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie · doi:10.1002/ange.201506030 · Cited by 131 · see citing works
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122 · see citing works
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 117 · see citing works
Zagar, T. M., Vujašković, Ž., Formenti, S. C., Rugo, H. S., Muggia, F. M., O'Connor, B. M., Myerson, R. J., Stauffer, P. R., Hsu, I.-C. J., Diederich, C. J., et al. (2014) · International Journal of Hyperthermia · doi:10.3109/02656736.2014.936049 · Cited by 111 · see citing works
PKN3 is required for malignant prostate cell growth downstream of activated PI 3‐kinase
Leenders, F., Möpert, K., Schmiedeknecht, A., Santel, A., Czauderna, F., Aleku, M., Penschuck, S., Dames, S., Sternberger, M., Röhl, T., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600345 · Cited by 108 · see citing works
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2671-x · Cited by 100 · see citing works
Pham, E., Birrer, M. J., Eliasof, S. D., Garmey, E. G., Lazarus, D. D., Lee, C. R., Man, S., Matulonis, U. A., Peters, C. G., Xu, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2810 · Cited by 96 · see citing works
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
de Jonge, M. J. A., Slingerland, M., Loos, W. J., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.015 · Cited by 91 · see citing works
The Recent Development of Propofol (DIPRIVAN®)
Thompson, K. A., & Goodale, D. B. (2000) · Intensive Care Medicine · doi:10.1007/pl00003783 · Cited by 85 · see citing works
Vascular-Targeted Photothermal Therapy of An Orthotopic Murine Glioma Model
Day, E. S., Zhang, L., Thompson, P. A., et al. (2012) · Nanomedicine · doi:10.2217/nnm.11.189 · Cited by 77 · see citing works
Phospholipases in biology and medicine
Kaiser, E., Chiba, P., & Zaky, K. (1990) · Clinical Biochemistry · doi:10.1016/0009-9120(90)90051-u · Cited by 76 · see citing works
An efficient synthesis of ferumoxytol induced by alternating-current magnetic field
Chen, B., Li, Y., Zhang, X., et al. (2016) · Materials Letters · doi:10.1016/j.matlet.2016.02.006 · Cited by 74 · see citing works
Borchard, G., Flühmann, B., & Mühlebach, S. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.08.009 · Cited by 66 · see citing works
EVOLUTION OF IV IRON COMPOUNDS OVER THE LAST CENTURY
Macdougall, I. C. (2009) · Journal of Renal Care · doi:10.1111/j.1755-6686.2009.00127.x · Cited by 60 · see citing works
Duramad, O., Laysang, A., Li, J., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.11.022 · Cited by 53 · see citing works
Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain
Mastorakos, P., Song, E., Zhang, C., Berry, S., Park, H. W., Kim, Y., Park, J., Lee, S., Suk, J. S., & Hanes, J. S. (2015) · Small · doi:10.1002/smll.201502554 · Cited by 51 · see citing works
Carnevale, J. C., & Ko, A. H. (2015) · Future Oncology · doi:10.2217/fon.15.333 · Cited by 50 · see citing works
On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage
Lane, D. P., Midgley, C., Hupp, T. R., Lü, X., Vojtěšek, B., & Picksley, S. M. (1995) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1995.0013 · Cited by 46 · see citing works
Selective nanoparticle‐directed ablation of the canine prostate
Schwartz, J. A., Price, R. E., Gill‐Sharp, K. L., et al. (2011) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21039 · Cited by 44 · see citing works
Smith, J. A., Costales, A. B., Jaffari, M. V., et al. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215594415 · Cited by 39 · see citing works
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust, D. M., & Jameson, G. N. L. (1998) · PubMed · Cited by 28 · see citing works
A novel vaccine adjuvant for recombinant flu antigens
Chang, S., Warner, J. F., Liang, L. R., et al. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.02.019 · Cited by 26 · see citing works
Anemia management in chronic kidney disease: Intravenous iron steps forward
Coyne, D. W., & Auerbach, M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21682 · Cited by 23 · see citing works
Phase I study of NBTXR3 nanoparticles, in patients with advanced soft tissue sarcoma (STS).
Bonvalot, S., Pechoux, C. L., de Baère, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10563 · Cited by 22 · see citing works
Wickham, T. J., & Futch, K. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p5-18-09 · Cited by 20 · see citing works
Barlas, S. (2013) · PubMed · Cited by 11 · see citing works
FDA advisors okay NeXstar's DaunoXome
Fox, J. L. (1995) · Nature Biotechnology · doi:10.1038/nbt0795-635 · Cited by 11 · see citing works
Chen, C., Kuo, M., Wang, J., et al. (2015) · Health Physics · doi:10.1097/hp.0000000000000326 · Cited by 11 · see citing works
Markets, venture investors and big pharma interest in RNAi soars
Bouchie, A. J. (2014) · Nature Biotechnology · doi:10.1038/nbt0314-203 · Cited by 9 · see citing works
Anselmo, A. C., & Mitragotri, S. (2016) · AIChE Journal · doi:10.1002/aic.15189 · Cited by 9 · see citing works
Self-citationChowdhury, R., & Ellis, P. (2014) · doi:10.1002/9783527682423.ch72 · Cited by 6 · see citing works
A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects
Keasey, N., Herse, Z., Chang, S., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.12653 · Cited by 6 · see citing works
Coelho, T., Suhr, O. B., Conceição, I. M., et al. (2015) · Neurology · doi:10.1212/wnl.84.14_supplement.s9.003 · Cited by 6 · see citing works
Larsen, J. E., Henriksen, J. R., Bæksted, M., et al. (2006) · Cited by 4 · see citing works
Sun, W., Ji, W., Hall, J. M., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201508399 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220 · see citing works
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · see citing works
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766 · see citing works
Self-citationThe evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works
Self-citationSmart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038 · see citing works
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302 · see citing works
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182 · see citing works
Self-citationThe in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154 · see citing works
Wang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153 · see citing works
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140 · see citing works
Gupta, P. K., Pappuru, S., Gupta, S., Patra, B., Chakraborty, D., & Verma, R. S. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.03.041 · Cited by 44 · see citing works
Microfluidic co-culture devices to assess penetration of nanoparticles into cancer cell mass
Jarvis, M., Arnold, M., Ott, J., Pant, K., Prabhakarpandian, B., & Mitragotri, S. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10079 · Cited by 32 · see citing works
Self-citation
- Authors
- Anselmo, A. C., & Mitragotri, S.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- University of California, Santa Barbara (US)
- Corresponding author
- Mitragotri, Samir
- Venue
- Bioengineering & Translational Medicine
- Publisher
- Wiley
- Published
- 2016-03
- Volume
- 1
- Issue
- 1
- Pages
- 10-29
- ISSN
- 2380-6761 (ISSN-L)
- PMC
- PMC5689513
- OpenAlex
- W2320866708
- Cited by
- 1,321
- References
- 135
- Citations by year
- 2026: 68 · 2025: 87 · 2024: 119 · 2023: 132 · 2022: 138 · 2021: 173 · 2020: 192 · 2019: 156 · 2018: 147 · 2017: 97 · 2016: 7 · 2015: 1 · 2014: 1 · 2012: 1
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bioengineering & Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Health (1R01HL129179-01)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanoparticle drug delivery, intravenous drug delivery, clinical translation of nanomedicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
